Tag Archives: durvalumab

Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma

phase 3 clinical trial

A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial will compare the immunotherapy drug durvalumab (IMFINZI) combined with chemotherapy against chemotherapy alone.  Results from the phase 2 trials of this combination released last year were promising. Tests showed that it extended mesothelioma survival by about 8 months with no debilitating side effects.  The randomized phase 3 clinical trial will try to confirm these results in a larger group of people. Mesothelioma Treatment with Durvalumab Durvalumab is an immune checkpoint inhibitor. Immune checkpoint inhibitors deactivate a cancer cell survival mechanism that helps cancer cells evade the immune system. Pleural mesothelioma and other types of cancer use proteins like PD-1 to … Continue reading Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma »

Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma

Immune Checkpoint Inhibitor

The immune checkpoint inhibitor durvalumab could become a standard part of first-line mesothelioma treatment if the results of a new study hold true in a Phase 3 trial.  Australian researchers have become the latest to show the benefit of adding durvalumab to first-line chemotherapy for pleural mesothelioma. Chemotherapy is usually the first thing doctors use to treat pleural mesothelioma. But as many as half of mesothelioma patients do not respond to it. Researchers around the world are hopeful that adding an immune checkpoint inhibitor like durvalumab will lead to better response rates. What is an Immune Checkpoint Inhibitor? Mesothelioma cells survive and thrive in part because they have ways of protecting themselves. Chemotherapy drugs are less likely to hurt them … Continue reading Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma »

Immunotherapy with Durvalumab: Record Survival in Inoperable Mesothelioma

immunotherapy drug durvalumab

There is new evidence that the immunotherapy drug durvalumab may make chemotherapy more effective for people with inoperable pleural mesothelioma. Researchers recently achieved record mesothelioma survival times with this combination. Mesothelioma is a rare cancer with a poor prognosis. Surgery can sometimes help if it is caught early. But only a small percentage of patients are candidates for mesothelioma surgery. Most have chemotherapy, which is only moderately effective.  But new research presented to the nation’s largest gathering of cancer doctors shows the immunotherapy drug durvalumab may help.  Doctors at Johns Hopkins combined durvalumab with standard mesothelioma chemotherapy. Study participants lived an average of 8 months longer than is typical with this disease.  If further studies confirm the benefit, it could … Continue reading Immunotherapy with Durvalumab: Record Survival in Inoperable Mesothelioma »